Roche Holding AG (LON:0QQ6)
London
· Delayed Price · Currency is GBP · Price in CHF 317.00
+2.00 (0.63%)
At close: Feb 21, 2025
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
n/a
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
210.56B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Genus | 668.80M |
Roche Holding AG News
- 3 days ago - Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology - GlobeNewsWire
- 4 days ago - Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare - South China Morning Post
- 4 days ago - Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche - Business Wire
- 10 days ago - Roche upgraded by UBS to buy on growth outlook - Seeking Alpha
- 11 days ago - FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 11 days ago - FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Business Wire
- 16 days ago - New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis - GlobeNewsWire
- 16 days ago - New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis - Business Wire